BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15389794)

  • 21. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
    Boesen A; Sundar K; Coico R
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
    Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
    Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ; Rosenberg SA
    Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
    Perambakam S; Xue BH; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
    Castellanos MR; Hayes RL; Maiman MA
    Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
    Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP
    Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
    Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M
    Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
    Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide.
    Inoue Y; Takaue Y; Takei M; Kato K; Kanai S; Harada Y; Tobisu K; Noguchi M; Kakizoe T; Itoh K; Wakasugi H
    J Urol; 2001 Oct; 166(4):1508-13. PubMed ID: 11547122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.